2025-03-24 - Analysis Report
## Merck & Co Inc (MRK) Stock Analysis

**0) Introduction:** This report analyzes Merck & Co Inc (MRK), a leading pharmaceutical company, based on provided financial and performance data.  We will examine its performance relative to the S&P 500 (VOO), recent price movements, key indicators, earnings, and financial information.

**1) Performance Relative to S&P 500:**

Merck & Co Inc (MRK) is a global pharmaceutical company known for its diverse portfolio of prescription medications, vaccines, and animal health products.

* **Cumulative Return (MRK):** 46.35%
* **Cumulative Return (VOO):** 104.98%
* **Return Difference:** -58.6%
* **Relative Divergence:** 25.8% (This means MRK's underperformance relative to VOO is at the 25.8th percentile of its historical range of under/outperformance.  It does *not* imply MRK is 25.8% less valuable.)

The provided data shows that MRK significantly underperformed the S&P 500 over the analyzed period. While the historical range suggests some periods of underperformance, the current gap is notable.  The Alpha and Beta analysis (below) provides further context.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 1.0% | 11.8% | -0.28 | 109.0 |
| 2016-2018  | 46.0% | 11.8% | 0.28 | 152.5 |
| 2017-2019  | 45.0% | 11.8% | -0.14 | 186.5 |
| 2018-2020  | 32.0% | 9.4% | 0.05 | 173.1 |
| 2019-2021  | 2.0% | 14.2% | -0.68 | 176.1 |
| 2020-2022  | 36.0% | 14.2% | 0.27 | 263.1 |
| 2021-2023  | 45.0% | 14.2% | 0.22 | 265.8 |
| 2022-2024  | 13.0% | 9.5% | -0.20 | 249.1 |
| 2023-2025  | -29.0% | 79.1% | -0.75 | 235.2 |

The table shows fluctuating performance and Alpha values.  Positive Alpha suggests outperformance relative to the market, while negative Alpha indicates underperformance.  The Beta values show substantial variation across periods, indicating varying levels of market sensitivity. The high MDD (Maximum Drawdown) values in some years highlight periods of significant risk.

**2) Recent Price Movement:**

* **Closing Price:** $93.11
* **Previous Close:** $94.73
* **Change:** -$1.71 (a -1.81% decrease)
* **5-Day Moving Average:** $94.27
* **20-Day Moving Average:** $92.72
* **60-Day Moving Average:** $93.65

The price is slightly below both the 5-day and 60-day moving averages, suggesting a potential short-term bearish trend.  However, it is above the 20-day moving average, indicating some underlying support.  The recent drop of $1.71 warrants further investigation of potential market factors driving this price movement.

**3) Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.42 (Medium Risk)
* **RSI:** 53.54 (Slightly above neutral; not overbought)
* **PPO:** 0.25 (Positive, suggesting potential upward momentum)
* **20-Day Relative Divergence Change:** -1.0 (Short-term downward trend)
* **Expected Return:** 1.1% (Long-term expected outperformance relative to the S&P 500)

The indicators present a mixed picture.  While the PPO is positive, the negative recent relative divergence and the slightly above-neutral RSI suggest caution. The MRI indicates a medium level of risk. The 1.1% long-term expected return suggests potential for long-term growth, surpassing the S&P 500 but further research is needed to solidify this projection.  The recent price drop of -1.71% indicates potential negative news impacting the price short term.


**4) Recent Earnings Analysis:**

| Date       | EPS  | Revenue       |
|------------|------|---------------|
| 2024-11-06 | $1.25 | $16.66B      |
| 2024-08-05 | $2.15 | $16.11B      |
| 2024-05-03 | $1.88 | $15.78B      |
| 2023-11-03 | $1.87 | $15.96B      |
| 2024-11-06 | $1.87 | $15.96B      |


There is a duplicated entry for 2024-11-06.  EPS and revenue figures show some fluctuation.  A deeper dive into the underlying reasons for these fluctuations is required for a complete analysis.  A consistent trend is not immediately clear.

**5) Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue    | Profit Margin |
|---------|------------|---------------|
| 2024-12-31 | $15.62B   | 75.50%        |
| 2024-09-30 | $16.66B   | 75.51%        |
| 2024-06-30 | $16.11B   | 76.76%        |
| 2024-03-31 | $15.78B   | 77.56%        |
| 2023-12-31 | $14.63B   | 73.26%        |

Revenue shows slight fluctuations, but generally strong. Profit margins are high and mostly consistent.


**Capital and Profitability:**

| Quarter | Equity     | ROE           |
|---------|------------|---------------|
| 2024-12-31 | $46.31B   | 8.08%         |
| 2024-09-30 | $44.50B   | 7.09%         |
| 2024-06-30 | $43.58B   | 12.52%        |
| 2024-03-31 | $40.36B   | 11.80%        |
| 2023-12-31 | $37.58B   | -3.26%        |

Equity is steadily increasing, but ROE fluctuates significantly. The negative ROE in 2023-12-31 requires further investigation.


**6) Overall Conclusion:**

MRK's performance has lagged behind the S&P 500 over the analyzed period. While the company shows high profit margins and increasing equity, inconsistent earnings and fluctuating ROE raise concerns.  Recent price movements suggest a potential short-term bearish trend. Technical indicators offer a mixed signal.  The 1.1% long-term expected return, if realized, may compensate for current underperformance, making further research crucial. A thorough examination of the causes for fluctuating EPS, revenue, and ROE is needed for a more complete and confident assessment of MRK's future prospects.  Further analysis of the duplicated data point and the negative ROE is required.
